How to buy Catalyst Biosciences stock

Catalyst Biosciences, Inc is a biotechnology business based in the US. Catalyst Biosciences shares (CBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Biosciences employs 56 staff and has a trailing 12-month revenue of around 0.00.

Catalyst Biosciences share price

Use our graph to track the performance of CBIO stocks over time.

Catalyst Biosciences shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$4.05 - $8.22
50-day moving average	$5.25
200-day moving average	$5.87
Wall St. target price	$18.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.96

Buy Catalyst Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Catalyst Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Catalyst Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Catalyst Biosciences under- or over-valued?

Valuing Catalyst Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalyst Biosciences's PEG ratio

Catalyst Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalyst Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Catalyst Biosciences financials

Revenue TTM	$20.9 million
Gross profit TTM	$-40,390,000
Return on assets TTM	-36.56%
Return on equity TTM	-77.89%
Profit margin	-268.48%
Book value	$3.44
Market capitalisation	$162.9 million

TTM: trailing 12 months

Shorting Catalyst Biosciences shares

There are currently 1.1 million Catalyst Biosciences shares held short by investors – that's known as Catalyst Biosciences's "short interest". This figure is 13.8% up from 1.0 million last month.

There are a few different ways that this level of interest in shorting Catalyst Biosciences shares can be evaluated.

Catalyst Biosciences's "short interest ratio" (SIR)

Catalyst Biosciences's "short interest ratio" (SIR) is the quantity of Catalyst Biosciences shares currently shorted divided by the average quantity of Catalyst Biosciences shares traded daily (recently around 324521.93732194). Catalyst Biosciences's SIR currently stands at 3.51. In other words for every 100,000 Catalyst Biosciences shares traded daily on the market, roughly 3510 shares are currently held short.

However Catalyst Biosciences's short interest can also be evaluated against the total number of Catalyst Biosciences shares, or, against the total number of tradable Catalyst Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalyst Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Catalyst Biosciences shares in existence, roughly 40 shares are currently held short) or 0.0365% of the tradable shares (for every 100,000 tradable Catalyst Biosciences shares, roughly 37 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catalyst Biosciences.

Find out more about how you can short Catalyst Biosciences stock.

Catalyst Biosciences share dividends

We're not expecting Catalyst Biosciences to pay a dividend over the next 12 months.

Have Catalyst Biosciences's shares ever split?

Catalyst Biosciences's shares were split on a 1:15 basis on 12 February 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catalyst Biosciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Catalyst Biosciences shares which in turn could have impacted Catalyst Biosciences's share price.

Catalyst Biosciences share price volatility

Over the last 12 months, Catalyst Biosciences's shares have ranged in value from as little as $4.05 up to $8.22. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Biosciences's is 2.064. This would suggest that Catalyst Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Catalyst Biosciences overview

Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc.

Frequently asked questions

• What percentage of Catalyst Biosciences is owned by insiders or institutions?

  Currently 3.348% of Catalyst Biosciences shares are held by insiders and 56.476% by institutions.

• How many people work for Catalyst Biosciences?

  Latest data suggests 56 work at Catalyst Biosciences.

• When does the fiscal year end for Catalyst Biosciences?

  Catalyst Biosciences's fiscal year ends in December.

• Where is Catalyst Biosciences based?

  Catalyst Biosciences's address is: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080

• What is Catalyst Biosciences's ISIN number?

  Catalyst Biosciences's international securities identification number is: US14888D2080

• What is Catalyst Biosciences's CUSIP number?

  Catalyst Biosciences's Committee on Uniform Securities Identification Procedures number is: 14888D109